![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
9MB |
![[thumbnail of Supplementary Materials]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Materials)
7MB |
| Item Type: | Review |
|---|---|
| Title: | Prognostic value of CD163(+) macrophages in solid tumor malignancies: a scoping review |
| Creators Name: | Mathiesen, H., Juul-Madsen, K., Tramm, T., Vorup-Jensen, T., Møller, H.J., Etzerodt, A. and Andersen, M.N. |
| Abstract: | Tumor-associated macrophages (TAMs) play crucial roles in development and progression of malignant diseases. Notably, CD163(+) TAMs likely perform specific pro-tumorigenic functions, suggesting that this subset may serve as both prognostic biomarkers and targets for future anti-cancer therapy. We conducted a scoping review to map the current knowledge on the prognostic role of CD163(+) TAMs in the five most lethal cancers worldwide: Lung, colorectal, gastric, liver, and breast cancer. For all cancer types, most studies showed that high tumoral presence of CD163(+) cells was associated with poor patient outcome, and this association was more frequently observed when CD163(+) cells were measured at the tumor periphery compared to more central parts of the tumor. These results support that CD163(+) TAMs represent a biomarker of poor patient outcome across a variety of solid tumors, and highlight the relevance of further investigations of CD163(+) TAMs as targets of future immunotherapies. |
| Keywords: | Tumor-Associated Macrophage, CD163, Cancer, Solid Tumor Malignancy, Patient Prognosis, Targeted Immunotherapy, Animals |
| Source: | Immunology Letters |
| ISSN: | 0165-2478 |
| Publisher: | Elsevier |
| Volume: | 272 |
| Page Range: | 106970 |
| Date: | April 2025 |
| Official Publication: | https://doi.org/10.1016/j.imlet.2025.106970 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
